Our first ZS portfolio and business development quarterly webinar of the year offered key insights for pharma leaders executing their 2024 strategies. This report, based on that same data, highlights:

• New drug success: Launches and revenue generated by new molecular entities approved in 2023
• Industry growth drivers: Which types of organizations are fueling the industry’s overall valuation increase
• Funding innovation: New funding avenues pharmaceutical companies are exploring
• Clinical trial trends: The reasons behind the decline in clinical trial volume
• Investment hotspots: Therapeutic areas attracting the most deal activity

Complete this form to stay in the loop.